SEC – ‘UPLOAD’ from 2/18/21 re: Amgen Inc. – ‘TEXT-EXTRACT’

On:  Thursday, 2/18/21, at 5:30pm ET   ·   Delayed-Release:  Filing ¶  –  Release Delayed   ·   Accession #:  0-21-2057

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Delayed-Release Comment or Other Letter from the SEC
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: LETTER      Comment or Other Letter from the SEC                 PDF     28K 
 2: TEXT-EXTRACT  Comment or Other Letter from the SEC - PDF's         1      5K 
                Text                                                             

‘TEXT-EXTRACT’   —   Comment or Other Letter from the SEC – PDF’s Text

United States securities and exchange commission logo                           

February 18, 2021           

Robert A. Bradway                                                 
Chairman of the Board, Chief Executive Officer and President      
AMGEN INC                                                         
One Amgen Center Drive                                            
Thousand Oaks, California 91320-1799                              

                                             Re: AMGEN INC
                                                    Registration
Statement on Form S-4                                                           
                                                         Filed February 9,
2021                                                                            
                                                           File No. 333-252898

Dear Mr. Bradway:                                                 

        This is to advise you that we have not reviewed and will not
review your registration                                                        
statement.                                                        

      Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you                                                     
      that the company and its management are responsible for the accuracy and
adequacy of their                                                               
     disclosures, notwithstanding any review, comments, action or absence of
action by the staff.                                                            

                                                       Please contact Margaret
Schwartz at 202-551-7153 with any questions.                                    

Sincerely,                  

   Division of Corporation Finance

Office of Life Sciences     
      cc:                                              R. Charles Cassidy III,
Esq.                                                                            

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘UPLOAD’ Filing		Date		Other Filings
Filed on:		2/18/21		4,  UPLOAD
		2/9/21		10-K,  4,  CORRESP,  S-4,  UPLOAD
				List all Filings